Davis D W, McConkey D J, Abbruzzese J L, Herbst R S
1Department of Cancer Biology, Unit 173, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Br J Cancer. 2003 Jul 7;89(1):8-14. doi: 10.1038/sj.bjc.6601035.
Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors.
目前正在研发的新型抗血管生成药物最终可能对实体瘤更有效，且毒性比细胞毒性化疗更低。由于血管生成抑制剂的早期临床试验，研究人员开始认识到靶向血管生成的复杂性，以及认识到开发临床上有用的抗血管生成疗法将比最初想象的更具挑战性。现在很明显，评估这些药物生物活性的新方法和替代标志物对其成功开发至关重要。这篇综述总结了目前关于血管生成抑制剂替代标志物开发的临床可用数据。
